

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: RF2/18 - Diagnostics of Rheumatoid Arthritis and ASLO

Dead line: 21.09.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}

Set of samples 2

(237) anti-streptolysin O (ASLO) [KU/L] 146 131 126 96%

Samples and groups

Sample A2

Sample	RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(1) Abbott	481	38	8,0	13	0	CVPG	481	26	24%	365	597	13	13
(12) Beckman Coulter	573	47	8,2	12	0	CVPG	573	33	24%	435	711	12	12
(58) Beckman Coulter (Olympus)	735	31	4,3	38	0	CVPG	735	12	24%	558	912	38	38
(60) Roche	674	40	5,9	37	0	CVPG	674	16	24%	512	836	37	37
(115) BioSystems	653	170	25	8	0	CVPG	653	130	24%	496	810	8	8
(149) Siemens (Dade)	696	42	6,1	9	1	CVPG	696	32	24%	528	864	9	9
(179) Siemens (Bayer)	760	66	8,7	14	0	CVPG	760	43	24%	577	943	14	14
Other				15	0							0	0

1x 5, 1x 40, 1x 46, 2x 49, 1x 116, 2x 166, 3x 177, 3x 178, 1x 999

Sample B2

Sample	RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(1) Abbott	105	7,4	7,0	13	0	CVPG	105	5,0	24%	79,8	131	13	13
(12) Beckman Coulter	90,6	12	13	12	0	CVPG	90,6	8,4	24%	68,8	113	12	12
(58) Beckman Coulter (Olympus)	131	4,6	3,5	38	0	CVPG	131	1,8	24%	99,5	163	38	38
(60) Roche	150	6,3	4,2	37	0	CVPG	150	2,5	24%	114	186	37	37
(115) BioSystems	118	24	20	8	0	CVPG	118	18	24%	89,6	147	8	8
(149) Siemens (Dade)	162	13	8,2	9	1	CVPG	162	10	24%	123	201	9	9
(179) Siemens (Bayer)	148	8,6	5,8	14	0	CVPG	148	5,7	24%	112	184	14	14
Other				15	0							0	0

1x 5, 1x 40, 1x 46, 2x 49, 1x 116, 2x 166, 3x 177, 3x 178, 1x 999

st_kn_p

End of report

Printed: 26.09.2018